Brokers Offer Predictions for Syros Pharmaceuticals Inc’s FY2019 Earnings (NASDAQ:SYRS)

Syros Pharmaceuticals Inc (NASDAQ:SYRS) – Stock analysts at Wedbush increased their FY2019 earnings per share (EPS) estimates for shares of Syros Pharmaceuticals in a note issued to investors on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of ($1.77) per share for the year, up from their prior forecast of ($1.79). Wedbush also issued estimates for Syros Pharmaceuticals’ Q1 2020 earnings at ($0.39) EPS, Q2 2020 earnings at ($0.40) EPS, Q3 2020 earnings at ($0.41) EPS, Q4 2020 earnings at ($0.37) EPS, FY2020 earnings at ($1.56) EPS, FY2021 earnings at ($1.49) EPS, FY2022 earnings at ($1.39) EPS and FY2023 earnings at ($1.08) EPS.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its earnings results on Tuesday, November 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.01. Syros Pharmaceuticals had a negative net margin of 3,115.38% and a negative return on equity of 84.49%. The company had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.43 million.

Other equities analysts have also issued research reports about the stock. BidaskClub upgraded shares of Syros Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, October 18th. Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a research report on Tuesday, November 12th. Piper Jaffray Companies reduced their price target on shares of Syros Pharmaceuticals from $24.00 to $18.00 in a research report on Thursday, October 17th. HC Wainwright restated a “hold” rating and set a $10.00 price target on shares of Syros Pharmaceuticals in a research report on Wednesday. Finally, Zacks Investment Research lowered shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $13.46.

Syros Pharmaceuticals stock opened at $4.99 on Friday. The company has a market capitalization of $222.39 million, a PE ratio of -2.61 and a beta of 1.49. The firm’s fifty day moving average is $7.08 and its 200 day moving average is $7.94. The company has a quick ratio of 8.11, a current ratio of 4.92 and a debt-to-equity ratio of 0.20. Syros Pharmaceuticals has a 12-month low of $4.88 and a 12-month high of $11.93.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC lifted its holdings in Syros Pharmaceuticals by 863.4% during the third quarter. Tower Research Capital LLC TRC now owns 2,688 shares of the company’s stock valued at $28,000 after purchasing an additional 2,409 shares during the last quarter. Bank of Montreal Can lifted its holdings in Syros Pharmaceuticals by 11,319.2% during the second quarter. Bank of Montreal Can now owns 2,969 shares of the company’s stock valued at $27,000 after purchasing an additional 2,943 shares during the last quarter. A.R.T. Advisors LLC purchased a new stake in Syros Pharmaceuticals during the second quarter valued at about $119,000. Susquehanna International Group LLP purchased a new stake in Syros Pharmaceuticals during the second quarter valued at about $133,000. Finally, Algert Global LLC purchased a new stake in Syros Pharmaceuticals during the second quarter valued at about $166,000. 93.14% of the stock is currently owned by institutional investors and hedge funds.

In other Syros Pharmaceuticals news, insider Jeremy P. Springhorn acquired 9,879 shares of the company’s stock in a transaction on Monday, November 11th. The shares were acquired at an average cost of $4.99 per share, with a total value of $49,296.21. Following the completion of the acquisition, the insider now directly owns 24,879 shares in the company, valued at $124,146.21. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 14.80% of the stock is owned by corporate insiders.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for cancer and monogenic diseases, and building a pipeline of gene control medicines. Its lead product candidates include SY-1425, a selective retinoic acid receptor alpha agonist, which is in a Phase II clinical trial for genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome; SY-1365, a selective cyclin-dependent kinase 7 (CDK7) inhibitor, which is in a Phase I clinical trial that is used for treating patients with solid tumors and blood cancers, including ovarian and breast cancer; and SY-5609, a CDK7 inhibitor, which is in preclinical studies to treat oncology patients.

See Also: Trading based on a resistance level

Earnings History and Estimates for Syros Pharmaceuticals (NASDAQ:SYRS)

Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.